Navigation Links
Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
Date:3/2/2011

NEW YORK and OSAKA, Japan, March 2, 2011 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.

ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.

Under the terms of the agreement, ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda. Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

"Takeda's strength in CNS drug development and commercialization complements ITI's innovative approach to discovery, research and development," said Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc. "We are delighted to be working together with Takeda to advance the development of our novel PDE1 inhibitors. This program represents a unique approach to the treatment of cognitive impairment associated with schizophrenia (CIAS) and other disorders."

"We are able to enhance our central nervous system pipeline, one of our Core Therapeutic Areas, through this collaboration," said Shigenori Ohkawa, a member of the Board and Executive Vice President, Chief Scientific Officer of Takeda Pharmaceutical Company Limited. "We believe that ITI's PDE1 inhib
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces the Successful Completion of a Phase Ib/II Study of ITI-007 in Patients with Schizophrenia
2. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
3. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
4. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
5. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
6. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
7. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
8. Intra-Cellular Therapies Presents Preclinical Data From Schizophrenia and Sleep Maintenance Programs
9. Reportlinker Adds Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
10. Reportlinker Adds Early Stage Drug Discovery in Disease Segments - Innovation Focuses on Stem Cell Therapies and Gene Therapies
11. The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... The American Association for Homecare (AAHomecare) is ... has joined the AAHomecare Corporate Partner Program. ... have been actively involved in AAHomecare for much of ... grown into a major global manufacturer of home medical ... to increase efforts on behalf of the HME sector ...
(Date:9/19/2014)... 2014 Larry J. Merlo , President and ... speak before the National Press Club in Washington, ... move to stop selling tobacco products and its leadership in ... "Dramatic changes in our health care system pose ... Merlo has said. "CVS Health has a truly unique combination ...
(Date:9/19/2014)...  Lpath, Inc. (NASDAQ: LPTN ), ... today that it has entered into definitive agreements ... and 3,605,042 unregistered warrants in a registered direct ... share of common stock and one unregistered warrant ... will be $3.475.  The warrants have an exercise ...
Breaking Medicine Technology:Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 2CVS Health CEO to Address National Press Club on Landmark Decision to Quit Tobacco, Leadership in Health Care Innovation 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... , BEDFORD, Ohio , Jan. 14 ... is pleased to announce FDA approval for the addition of ... line. This product is AP rated and is equivalent to ... for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is indicated ...
... , , BETHLEHEM, Pa. , Jan. 13 ... and easy-to-use WHIN ® Safe Huber Needle , an implantable ... a single Huber Needle and provides clinicians with advanced protection ... http://www.newscom.com/cgi-bin/prnh/20081022/NYW008LOGO ) , There are three models of the WHIN ® ...
Cached Medicine Technology:Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 2Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 3Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection 4B. Braun Introduces WHIN(R) Safe Huber Needle 2B. Braun Introduces WHIN(R) Safe Huber Needle 3B. Braun Introduces WHIN(R) Safe Huber Needle 4
(Date:9/20/2014)... Increases in household, construction and ... treatment volumes. However, government regulations and higher landfill ... According to IBISWorld industry analyst Alen Allday, “over ... at reducing the volume of waste generated, and ... Still, a large proportion of waste generated by ...
(Date:9/20/2014)... York (PRWEB) September 20, 2014 ... to grow in federal court, Bernstein Liebhard LLP ... Drug Administration (FDA) have voted overwhelmingly to recommend ... in men be subjected to further study in ... a report published on September 18th by Bloomberg.com, ...
(Date:9/20/2014)... Sept. 20, 2014 (HealthDay News) -- As flu season ... infection is to get a flu shot and a ... A primary care doctor can vaccinate people against the ... patients may have. Retail stores may provide flu shots ... advice, said Dr. Jorge Parada, medical director of infection ...
(Date:9/20/2014)... New York (PRWEB) September 20, 2014 ... morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgeries ... yet another insurer has announced plans to end ... posted on its website last month, Harrisburg, Pennsylvania-based ... effective November 1, 2014. The insurer said its ...
(Date:9/20/2014)... Traditionally dentists have advised their patients against drinking coffee and ... re-visiting that advice and changing his stance after considering two ... on oral health. “There’s good news and great news,” says ... in protecting against gum disease, and red wine can help ... from the September 2014 issue of Boston University School ...
Breaking Medicine News(10 mins):Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 2Health News:As Testosterone Lawsuits Grow, Bernstein Liebhard LLP Notes Overwhelming Vote Calling for Further Study of Testosterone Heart Risks 3Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3
... Breakthroughs in the Field , , ... and the American Friends of The Hebrew University ... co-chair of the Bill & Melinda Gates Foundation, with its inaugural ... New York Hilton. , , ...
... MEXICO CITY and PRINCETON, N.J., Dec. 5 MetLife ... life insurance company in Mexico, and a leading provider ... today that it has partnered with Assist America, Inc., ... through employee benefit plans, to protect 500,000 of its ...
... soon be possible, thanks to a discovery made by ... Coastal Health Research Institute neuroscience researchers. , The researchers ... previously found to that cause cell death following a ... following head trauma or a stroke. , The findings, ...
... A Better Tomorrow, a fast growing,Southern California-based rehabilitation center, is ... and the United,States. , ... for their,addictions," said Sylvia Reynolds, a bilingual therapist from A ... "And these calls are ...
... and Families Embrace Life to the Fullest , ... a world-leading developer and marketer of innovative medical technologies for ... the new global lifestyle magazine for people with an ostomy. ... articles on living a healthy and active life after ostomy ...
... Anthem Blue Cross and Blue Shield,in New Hampshire has ... the current issue of U.S. News & World Report/NCQA America,s ... best health plans,is the result of outstanding overall performance in ... Anthem Blue Cross and Blue Shield ...
Cached Medicine News:Health News:Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem 2Health News:Event Honoring Bill Gates Raises Over $1.5 Million for Sustainable Agriculture Research at The Hebrew University of Jerusalem 3Health News:MetLife Mexico Life Insurance Company Partners with Assist America for Global Emergency Medical Assistance Services 2Health News:New target discovered to treat epileptic seizures following brain trauma or stroke 2Health News:Southern California Rehabilitation Clinic is Hiring Bilingual Therapists to Better Serve the Hispanic Communities of Mexico and the United States 2Health News:ConvaTec Launches New Lifestyle Magazine for People With an Ostomy 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List 2Health News:Anthem Blue Cross and Blue Shield in New Hampshire Ranks Among Top Insurers on U.S. News & World Report / National Committee for Quality Assurance Best Health Plans List 3
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad selection ... a wide variety of ophthalmic procedures. ... sterile, complete with a safety cap ... " position when not in use, ...
... The B-VAT® PC visual acuity system ... features of the B-VAT II. The system ... sequencing, contrast sensitivity testing and animated characters. ... the operator has single letter, single line ...
Medicine Products: